NCT03939897: Fulvestrant and Abemaciclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive and HER2 Negative Stage IV Breast Cancer

NCT03939897
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have no more than 1 prior chemotherapy in the metastatic setting- there is no limit on endocrine therapies; For patients enrolling in phase 1, prior fulvestrant, CDK4/6 inhibitor, & everolimus is allowed; For patients enrolling in phase 2, they must demonstrate resistance to endocrine therapy in the metastatic setting- see trial for details
Exclusions: Patients with progressive brain metastases- though patients with a history of treated brain metastases are eligible for phase I portion- see trial for details
https://ClinicalTrials.gov/show/NCT03939897

Comments are closed.

Up ↑